Request availability and a quotation for your required quantity and destination.
| Product | Semaglutide 3 mg - Rybelsus Tablet |
|---|---|
| Categories | Weight Loss |
| Availability | Confirmed on enquiry |
Product listing is not a recommendation to use this medicine. Prescription and destination requirements apply where relevant.
Active ingredient: Semaglutide 3 mg
Dosage form: Oral tablet
Medicine class: GLP-1 receptor agonist
Prescription status: Prescription medicine
Rybelsus 3 mg contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used as part of the treatment of adults with type 2 diabetes mellitus. The 3 mg strength is generally used as the initial dose to help the body adjust to oral semaglutide; it is not intended as the maintenance dose for glycaemic control. Treatment and dose escalation should be directed by a qualified healthcare professional.
Semaglutide is used alongside diet and exercise to improve blood glucose control in adults with type 2 diabetes. Suitability depends on the patient’s medical history, current medicines and local prescribing guidance. It is not a treatment for type 1 diabetes.
Semaglutide mimics the activity of GLP-1, a naturally occurring hormone involved in glucose regulation. It helps increase insulin release when blood glucose is elevated, reduces glucagon secretion and slows gastric emptying. These effects can improve glycaemic control and may reduce appetite in some patients.
Follow the prescription and the patient information supplied with the medicine. Rybelsus is taken on an empty stomach after waking with a small amount of plain water. The tablet should be swallowed whole. Patients should wait at least 30 minutes before eating, drinking or taking other oral medicines. Do not split, crush or chew the tablet.
Important: Do not change strength or dose without medical advice. Different oral semaglutide formulations may not be interchangeable milligram-for-milligram.
Semaglutide may not be suitable for everyone. Patients should tell their prescriber about all medical conditions and medicines before treatment. Particular care may be required with a history of pancreatitis, diabetic retinopathy, kidney problems, severe gastrointestinal symptoms, or when semaglutide is used with insulin or medicines that can cause hypoglycaemia.
Rybelsus is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or a previous serious hypersensitivity reaction to semaglutide or its ingredients. Seek urgent medical care for symptoms of a severe allergic reaction or severe, persistent abdominal pain.
Commonly reported effects with GLP-1 receptor agonist treatment include gastrointestinal symptoms such as nausea, abdominal discomfort, diarrhoea, vomiting or constipation. Side effects and their frequency can vary. Persistent or severe symptoms should be discussed promptly with a healthcare professional.
Cureiva Healthcare provides product information and handles international medicine enquiries subject to prescription requirements, destination-country rules and product availability. An enquiry does not replace consultation with a doctor and does not guarantee supply. Prescription medicines should only be used for the person for whom they were prescribed.
Consult the DailyMed Rybelsus prescribing information and the leaflet for your exact product and country. Different oral semaglutide formulations are not interchangeable milligram for milligram.
It is the initiation strength of oral semaglutide for eligible adults with type 2 diabetes; it is not a maintenance dose for glycaemic control.
No. For the 3/7/14 mg formulation it is generally taken for the first 30 days before a prescriber considers the next strength.
Follow the exact pack instructions. For the 3/7/14 mg formulation, take on waking on an empty stomach with up to 120 mL of plain water and wait at least 30 minutes before eating, drinking or taking other oral medicines.
No. Swallow tablets whole; do not split, crush or chew.
No. Semaglutide is a GLP-1 receptor agonist, not insulin.
Rybelsus is prescribed for type 2 diabetes; approved indications differ by country. Weight-management treatment requires an individual clinical assessment.
Yes, subject to availability, valid prescriptions where required and destination-country import regulations. An enquiry does not guarantee supply.
For the 3/7/14 mg formulation, skip the missed dose and take the next dose the following day. Follow your product leaflet and clinician’s advice.
Nausea, vomiting, diarrhoea, constipation and abdominal discomfort may occur. Seek urgent care for severe persistent abdominal pain or symptoms of a serious allergic reaction.
Sometimes, but a clinician must review interactions and the risk of hypoglycaemia, particularly with insulin or sulfonylureas.
This page is intended for general product education and enquiry support and is not a substitute for diagnosis, prescribing advice or the official patient information leaflet. Medical information should be reviewed against the current manufacturer information and applicable regulatory guidance before treatment decisions are made.
Last content review: October 2026